We screened 57 chemical probes, high-quality tool compounds, and relevant clinically used drugs to 12 investigate their effect on pro-inflammatory prostaglandin E 2 (PGE 2 ) production and interleukin-8 (IL-13 8) secretion in human whole blood. Freshly drawn blood from healthy volunteers and patients with 14 systemic lupus erythematosus (SLE) or dermatomyositis was incubated with compounds at 0.1 or 1 µM 15 and treated with lipopolysaccharide (LPS, 10 µg/mL) to induce a pro-inflammatory condition. Plasma 16 was collected after 24 hours for lipid profiling using liquid chromatography tandem mass spectrometry 17 (LC-MS/MS) and IL-8 quantification using enzyme-linked immunosorbent assay (ELISA). Each 18 compound was tested in at least four donors at one concentration based on prior knowledge of binding 19 affinities and in vitro activity. Our screening suggested that PD0325901 (MEK-1/2 inhibitor), trametinib 20 (MEK-1/2 inhibitor), and selumetinib (MEK-1 inhibitor) decreased while tofacitinib (JAK inhibitor) 21 increased PGE 2 production. These findings were validated by concentration-response experiment in two 22
Introduction 33
Inflammation is a highly controlled immune response to eliminate the cause of tissue injury or infection 34 and to initiate tissue repair back to homeostasis via resolution [1, 2] . However, inflammation is not 35 always terminated. Unresolved inflammation causes persistent pain, tissue degeneration, and loss of 36 function. In particular, inflammatory responses drive many autoimmune diseases [3] and inflammation 37 is a hallmark of cancer [4] . Thus, there is a great need for new therapies that are anti-inflammatory and 38 safe. 39
Prostaglandin E 2 (PGE 2 ) is a potent lipid mediator of inflammation and immune responses, and PGE 2 is 40 a central mediator of pain, edema, and cartilage erosion typically observed in the joints of rheumatoid 41 arthritis patients [5, 6] . In addition, PGE 2 is a promotor of the immunosuppressive tumor 42 microenvironment with major impact on tumor progression [4, 7, 8] . During inflammation, PGE 2 is 43 synthesized via conversion of arachidonic acid by cyclooxygenases (COX-1 and COX-2) into unstable 44 PGH 2 that is further metabolized by the inducible terminal synthase microsomal prostaglandin E 45 synthase-1 (mPGES-1) to generate PGE 2 . Multiple non-steroidal anti-inflammatory drugs (NSAIDs) 46 exist in clinical practice that unselectively decrease PGE 2 production via inhibition of COX, but these 47 drugs are all associated with adverse effects. Hence, selective inhibition of PGE 2 production with small 48 molecule inhibitors could therefore be a desirable therapeutic strategy in inflammation and cancer [9] . 49
Interleukin-8 (IL-8) is a potent chemoattractant and activator of neutrophils. IL-8 signalling is implicated 50 in multiple chronic inflammatory diseases [10] and cancer [11] . For example, a recent meta-analysis 51 concluded that patients suffering from systemic lupus erythematosus (SLE) have increased levels of 52 In this study, we aimed to evaluate the effect of 57 chemical probes, high-quality tool compounds, and 63 relevant control drugs on eicosanoid production and IL-8 secretion in human whole blood. A chemical 64 probe is defined as "… a selective small-molecule modulator of a protein's function that allows the user 65 to ask mechanistic and phenotypic questions about its molecular target in biochemical, cell-based or 66 animal studies" [21] , and these compounds follow the criteria of in vitro potency (IC 50 or Kd <100 nM), high selectivity versus other protein subfamilies (>30-fold), and on-target cell activity at 1 µM. The 68 chemical probes and other high-quality tool compounds included are mainly epigenetic modulators and 69 kinase inhibitors that were produced in academic collaborations or donated by pharmaceutical 70 companies within the Structural Genomic Consortium (SGC, www.thesgc.org), which aims to 71 investigate novel targets for drug development in open science and in collaboration with the 72 pharmaceutical industry. These inhibitors were tested here at one concentration (in triplicates, n=4-15 73 donors) based on previous knowledge of binding affinities and toxicity in vitro, as assessed using other 74 validated assays in our laboratories (https://ultra-dd.org/tissue-platforms/cell-assay-datasets). 75 
Materials and methods

Collection of blood 81
Peripheral venous blood was drawn from 10 females and 6 males, aged between 27 and 81 years. Healthy 82 controls (n=4) and two patient groups were included: systemic lupus erythematosus (n=9) and 83 dermatomyositis (n=3). The blood was collected in tubes containing sodium heparin (1000 U/mL). 84
Inhibitors 85
The inhibitors (chemical probes and other high-quality tool compounds) tested here were obtained 86 through the SGC (www.thesgc.org) and supplied by different distributers ( Supplementary Table 1 ). 87 Table 1 ) were reconstituted at 10 mM in DMSO (D2250, 88
Inhibitors and control drugs (Supplementary
Sigma-Aldrich), aliquoted in Eppendorf tubes or 96-well plates, and kept at -80°C. A fresh aliquot was 89 used at each experiment. Diclofenac (dual COX-1/2 inhibitor) was used as positive control for inhibition 90 of prostanoid production. LPS (L6529, Sigma-Aldrich) was reconstituted in PBS (D8537, Sigma-91 Aldrich) to a final concentration of 0.1 mg/mL and kept at +8°C. 92
Whole blood assay 93
Inhibitors and vehicle control (DMSO) were diluted in PBS at room temperature with no direct light on. 94
The treatments were prepared in 25 µL portions to U-shaped 96-well plate and 200 µL of freshly drawn 95 heparin blood (<2 hrs at room temperature) was added to the plate. The plate was incubated at 37°C for 96 30 min and then 25 µL of 0.1 mg/mL LPS in PBS was added followed by pipetting up and down 3 times 97 (final concentration of LPS was 10 µg/mL). The tested concentration for inhibitor was 0.1 or 1 µM 98 Table 1 ). The plate was incubated for 24 hrs at 37°C and then centrifuged at 3000 g for 99 and from this 20 µL was transferred to a second plate (for IL-8 quantification). The plates were sealed 101 with aluminum foil and stored at -80°C. 102
Extraction of lipids 103
Plasma samples (80-240 µL) were thawed on ice and spiked with 50 µL deuterated internal standard 104 mix containing 17 ng 6-keto-PGF 1α -d4, 8 ng PGF 2α -d4, 12 ng PGE 2 -d4, 8 ng PGD 2 -d4, 8 ng TXB 2 -d4, 105 and 8 ng 15-deoxy-Δ12,14PGJ 2 -d4 (Cayman Chemical Company) prepared in 100% methanol. Protein 106 precipitation was performed by addition of 800 µL 100% methanol, followed by vortexing, and 107 centrifugation at 3000 g for 10 min at 4°C. The supernatants were collected in a new plate and evaporated 108 under vacuum for 4 hrs. The evaporated samples (100-200 µL) were diluted to 1 mL with 0.05% formic 109 acid in water and then loaded onto Oasis HLB 1cc 30mg plate (Waters Corporation, USA) that had been 110 pre-conditioned with 1 mL of 100% methanol and 1 mL of 0.05% formic acid in water. The plate was 111 washed with 10% methanol, 0.05% formic acid in water and lipids were eluted with 100% methanol. 112
The eluates were dried under vacuum over-night and stored at -20°C until reconstituted in 50 µL of 20% 113 acetonitrile in water prior to analysis with liquid chromatography tandem mass spectrometry (LC-114
MS/MS). 115
Lipid profiling by LC-MS/MS 116
Lipids were quantified in negative mode with multiple reaction monitoring method, using a triple 117 quadrupole mass spectrometer (Acquity TQ detector, Waters) equipped with an Acquity H-class UPLC 118 (Waters). Eicosanoid were purchased from Cayman Chemicals and individually optimized for based on 119 precursor ion m/z, cone voltage, collision energy, and fragment ion m/z ( Supplementary Table 2 ). An 120 eicosanoid mix containing all standards of interest was used to check interference in the LC-MS/MS 121 analysis. LPC(14:0) and LPC(18:0) were used to set optimal analytical parameters for quantification of 122
LPCs. Separation of lipids was performed on a 50 x 2.1 mm Acquity UPLC BEH C18 column 1.7 µm 123 (Waters) with a 12 min stepwise linear gradient (20-95%) at a flowrate of 0.6 mL/min with 0.05% formic 124 acid in acetonitrile as mobile phase B and 0.05% formic acid in water as mobile phase A. Data were 125 analyzed using MassLynx software, version 4.1, with internal standard calibration and quantification to 126 external standard curves for prostanoids. LPCs were normalized as area-% within each injection. Only 127 lipids with peaks intensities of signal-to-noise greater than 10 (S/N >10) were considered in our data 128 analysis.
Data are presented as mean±SEM if not stated otherwise. Statistical analyses were performed using 134 GraphPad Prism 6 (GraphPad Sofware). One sample t-test was used to test significant difference. 135
Statistical significance level was set to p<0.05. 136
Results
137
Development of whole blood assay 138
The whole blood assay was developed to screen for changes in multiple eicosanoids. RvD2, LTB 4 , protectin DX, and 13-HODE; good LLOQ were 6-keto PGF 1α , PGD 2 , 5-HETE, 15-HETE, 149 and LTD 4 ; poor LLOQ were 15d-PGJ 2 , 12-HETE, 17-hydroxy DHA, and LTC 4 . The extraction recovery 150 rates were 33-125%. The response in plasma compared to 20% acetonitrile were 52-116% due to matrix 151 effects. The estimated LLOQ in 100 µL plasma was approximately 1 ng/mL for the best performing 152 eicosanoids including PGE 2 , TXB 2 , PGF 2α , RvD1, RvD2, and protectin DX. We can conclude that the 153 method provided similar quantitative performance in plasma for many eicosanoids. 154 LPS at 0.1-10 µg/mL increased PGE 2 and TXB 2 production in human whole blood, which are the two 155 dominant eicosanoids produced under these conditions [22] . All other eicosanoids were below the 156 LLOQ. We chose 10 µg/mL of LPS as our final concentration, yielding a robust amount of PGE 2 (49±4 157 ng/mL, n=5 donors) and TXB 2 (24±9 ng/mL, n=5 donors). The prostanoid production was completely 158 blocked using the dual COX-1/2 inhibitor diclofenac (10 µM). High concentration of DMSO (0.1%) 159 slightly decreased PGE 2 production by 20% (n=2 donors) while DMSO at 0.01% or 0.001% had no 160 effect. The intra-assay coefficient of variation (CV, n=20 technical replicates) was 12% and 11% for 161 PGE 2 and TXB 2 , respectively. The inter-assay CV for control material (n=3 donors) was 20% for PGE 2 162 and 30% for TXB 2 . This was performed on blood that was drawn, incubated, extracted, and analyzed at 163 separate occasions. The suppression in signal due to matrix effects and/or recovery efficiency varied 164 between donors and experiments, ranging from 10-70% suppression compared to signal in extracted 165 blank (mean ± SD, n=6 donors, PGE 2 : 45±25%, TXB 2 : 40±20%). In summary, 24 hrs incubation of 166 whole blood with 10 µg/mL LPS resulted in profound induction of the COX-1/2 products PGE 2 and 167 TXB 2 that was efficiently blocked by diclofenac at 10 µM.
Effect on PGE 2 and TXB 2 production 169
Our screening of inhibitors suggested that selected kinase inhibitors affected prostanoid production 170 (Figure 1) . The strongest reduction in PGE 2 production was observed by MEK-1 inhibitor PD0325901 171 (31±6%, p=0.001, n=4) and MEK-1/2 inhibitor trametinib (34±7%, p<0.0001, n=15). Moderate 172 suppression in PGE 2 concentration was found for MEK-1/2 inhibitor selumetinib (65±9%, p=0.02, n=5), 173 ERK-1/2 inhibitor SCH772984 (76±11%, p=0.04, n=13) and p38 inhibitor skepinone-L (76±8%, 174 p=0.01, n=13). However, the tested p38 inhibitor pamapimod did not affect PGE 2 production. Two of 175 these compounds decreased TXB 2 production, namely trametinib (63±6%, p=0.02, n=15) and 176 selumetinib (74±7%, p=0.02, n=5). Diclofenac, here used as a positive control for inhibition of 177 prostanoid production, blocked the prostanoid production while selective COX-2 inhibitor NS-398 178 inhibited only PGE 2 production, in agreement with previously reported data for these compounds in 179 whole blood assay [23] . The JAK inhibitor tofacitinib increased both PGE 2 (286±51%, p=0.01, n=6) 180 and TXB 2 (169±20%, p=0.02, n=6) production. The IRAK-1/4 inhibitor I slightly increased the 181 concentrations of PGE 2 (139±15%, p=0.04, n=7) and TXB 2 (133±8%, p=0.008, n=7). 182
We chose to investigate the strongest observed effects in more detail by performing concentration-183 response experiments for PD0325901, trametinib, selumetinib, and tofacitinib. All three MEK inhibitors 184 showed a concentration-dependent response on both PGE 2 and TXB 2 production while tofacitinib 185 showed a concentration-dependent response on PGE 2 production (Figure 2) . 186
Effect on IL-8 secretion 187
In line with the effect on prostanoid production, reduction in IL-8 secretion was found for PD0325901 188 (24±9%, p=0.03, n=3), trametinib (27±5%, p<0.0001, n=13), and selumetinib (45±10%, p=0.03, n=3) 189 (Figure 3) . Moderate reduction in IL-8 secretion was found for SCH772984 (62±9%, p=0.002, n=12) 190 and diclofenac (66±8%, p=0.003, n=11). We could also observe that tofacitinib increased IL-8 secretion 191 (225±57%, p=0.16, n=3), however not with statistical significance. 192
Effect on LPC profile 193
We measured LPC species within our targeted LC-MS/MS analysis. LPCs are mainly generated by 194 metabolism of membrane phosphatidylcholine by cytosolic phospholipase A 2 [24]. These lipids have 195 been reported to be involved in several cellular processes; sometimes with opposing effect depending 196 on degree of saturation, concentration, and biological context [25, 26] . We observed no difference in 197 total LPC or LPC profile when whole blood was treated with LPS neither did any of the tested inhibitors 198 alter the LPC profile (Figure 4) . 199
Discussion
200
We have tested the inhibitory effect on prostanoid production and IL-8 secretion in human whole blood 201 for 57 high-quality inhibitors with known target specificities and in vitro potencies. None of the tested epigenetic modulators, which are acting on demethylases, bromodomains, or methyltransferases, 203 affected PGE 2 or IL-8 concentration. Inhibition of MEK-1/2 or ERK decreased PGE 2 production and 204 IL-8 secretion in this assay. This effect was observed for allosteric inhibitor trametinib (MEK-1/2), non 205 ATP-competitive inhibitors PD0325901 (MEK-1) and selumetinib (MEK-1/2), and ATP-competitive 206 inhibitor SCH772984 (ERK-1/2). These kinase targets are part of the RAS/RAF/MEK/ERK signaling 207 transduction pathway, where inhibition of MEK prevents the downstream phosphorylation and 208 activation of ERK that ultimately regulates cellular responses such as survival, lipid metabolism, and 209 protein translation [27] . For example, MEK-1/2 inhibitor PD184352 decreased PGE 2 production in 210 melanoma cell line by decreased COX-2 expression due to inhibition of phosphorylation on ERK [28] 211 and trametinib reduced IL-8 production in melanoma cell line [29] . We found that our positive control 212 diclofenac for blocking prostanoid production decreased IL-8 secretion, which is explained by the fact 213 that PGE 2 stimulates IL-8 production in cultured cells [30] [31] [32] [33] . While our study mainly focused on 214 identifying inhibitory effects, we observed that JAK inhibitor tofacitinib increased both PGE 2 215 production and IL-8 secretion. Tofacitinib is used to treat rheumatoid arthritis and it is known that 216 tofacitinib can increase the expression of pro-inflammatory mediators, including PGE 2 , in macrophages 217 by acting inhibitory on the expression of anti-inflammatory IL- 10 [34] . The increased formation of pro-218 inflammatory PGE 2 and platelet activating thromboxane A 2 (as measured by stable metabolite TXB 2 ) in 219 human whole blood may be associated with the recently recognized increased risk of thromboembolism 220 associated with JAK inhibitors in treatment of rheumatoid arthritis [35] . We acknowledge that the 221 limitation of our study is the usage of one concentration per tested inhibitor. However, the used 222 concentrations were based on reported IC 50 and/or EC 50 values as well as solid experiences in our 223 laboratories using other validated assay systems (https://ultra-dd.org/index.php/tissue-platforms/cell-224 assay-datasets). We also demonstrated in concentration-response experiments that greater inhibitory 225 effect could be achieved by increasing the concentration for the MEK inhibitors. However, this increases 226 the risk of off-target effects and/or introduction of cellular toxicity that needs to be taken into account 227 in experimental design and interpretation of results. In conclusion, we identified inhibitors for MEK or 228 ERK as anti-inflammatory hits in our human whole blood assay. Based on the suppression in PGE 2 229 production and IL-8 secretion, further investigation of the MEK/ERK signaling pathway may inform 230 future therapeutic strategies to treat inflammatory diseases such as SLE and dermatomyositis. 231 Supplementary Table S1 . 368 Supplementary Table S2 . 369 
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